多发性骨髓瘤诊断治疗研究进展  

Advances in diagnosis and treatment of multiple myeloma

作　　者：赵凤仪 李新[1] 黄仲夏[1] Zhao Fengyi;Li Xin;Huang Zhongxia(Department of Hematology and Oncology,Bejing Chaoyang Hospital,Capital Medical University,Bejing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院血液与肿瘤科,北京100020

出　　处：《中国肿瘤临床与康复》2023年第1期54-60,共7页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：首都医科大学北京朝阳医院金种子科研基金(CYJZ202113);石景山重点专科建设项目。

摘　　要：多发性骨髓瘤(multiplemyeloma,MM)是一种以单克隆浆细胞恶性增殖为特点的疾病,约占血液系统恶性肿瘤的10%。临床上以溶骨性骨质破坏、肾功能不全、贫血、反复感染、高钙血症等为主要表现。MM是一类中老年疾病,男性发病率和死亡率均高于女性。从2006一2016年我国MM流行病学数据来看,MM发病率逐年升高而死亡率渐趋平稳,这表明随着多种新药的出现和治疗手段的进步,MM治疗疗效得到显著的提高。本文就MM的国内外诊治、分子分型和预后评价的最新进展展开综述。Multiple myeloma(MM)is a disease characterized by malignant proliferation of monoclonal plasma cells,accounting for about 10%of hematological malignancies.The main clinical manifestations are osteolytic bone destruction,renal insufficiency,anemia,infection and calcemia.MM is a kind of disease in middle-aged and elderly people,with higher morbidity and mortality in men than in women.According to the epidemiological data of MM in China from 2006 to 2016,the incidence of MM increased year by year,while the mortality rate was stable.This indicates that with the emergence of a variety of new drugs and the progress of treatment methods,the efficacy of MM treatment has been significantly improved.This article reviews the latest progress in the diagnosis,treatment,molecular classification and prognosis evaluation of MM at home and abroad.

关 键 词：多发性骨髓瘤 诊断 分子遗传学 治疗 预后 

分 类 号：R733.3[医药卫生—肿瘤]